Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2022

03.02.2022 | short review

Hepatocellular carcinoma—neoadjuvant systemic and local treatment concepts to improve resectability rates and oncological outcome

verfasst von: Iveta Urban, Florian Primavesi, Klaus Bogner, Claudia Bartsch, Marlene Trattner, Alexandra Schmid, Stefan Stättner

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Hepatocellular carcinoma (HCC) is one of the most common cancers with an increasing incidence and high mortality rate worldwide. Surgical resection is still an essential curative-intent treatment for improving the prognosis of patients with HCC. Due to the concomitance of HCC with cirrhosis, chronic liver disease, alcohol consumption and its complications, clinical treatment is challenging. Despite the rational approaches to prevention that have been developed, many patients are diagnosed at an advanced stage and are not eligible for surgical treatment, for example, because of poor underlying liver function or extrahepatic disease spread. The recurrence rates after curative resection still remain high. The implementation of neoadjuvant therapy in HCC management plays an important role in preventing tumor progression, but also shows promising results in downstaging HCC to enable surgical resection. The absence of randomized controlled trials leaves uncertainty in improving outcome, and consensus guidelines are lacking. In this review article, we summarize the clinical efficacy of evolving neoadjuvant treatments for patients with intermediate or advanced stage HCC.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
5.
Zurück zum Zitat Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344–54. CrossRef Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344–54. CrossRef
6.
Zurück zum Zitat Kulik L, Heimbach JK, Zaiem F, Almasri J, Prokop LJ, Wang Z, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis. Hepatology. 2018;67:381–400. CrossRef Kulik L, Heimbach JK, Zaiem F, Almasri J, Prokop LJ, Wang Z, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis. Hepatology. 2018;67:381–400. CrossRef
7.
Zurück zum Zitat Li C, Wang MD, Lu L, Wu H, Yu JJ, Zhang WG, et al. Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10 cm): a multicenter propensity matching analysis. Hepatol Int. 2019;13:736–47. CrossRef Li C, Wang MD, Lu L, Wu H, Yu JJ, Zhang WG, et al. Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10 cm): a multicenter propensity matching analysis. Hepatol Int. 2019;13:736–47. CrossRef
8.
Zurück zum Zitat Tustumi F, Ernani L, Coelho FF, Bernardo WM, Junior SS, Kruger JAP, et al. Preoperative strategies to improve resectability for hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Ooxford). 2018;20:1109–18. CrossRef Tustumi F, Ernani L, Coelho FF, Bernardo WM, Junior SS, Kruger JAP, et al. Preoperative strategies to improve resectability for hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Ooxford). 2018;20:1109–18. CrossRef
9.
Zurück zum Zitat Zhang T, Zhang L, Xu Y, Lu X, Zhao H, Yang H, et al. Neoadjuvant therapy and immunotherapy strategies for hepatocellular carcinoma. Am J Cancer Res. 2020;10(6):1658–67. PubMedPubMedCentral Zhang T, Zhang L, Xu Y, Lu X, Zhao H, Yang H, et al. Neoadjuvant therapy and immunotherapy strategies for hepatocellular carcinoma. Am J Cancer Res. 2020;10(6):1658–67. PubMedPubMedCentral
13.
Zurück zum Zitat Gao S, Yang Z, Zheng Z, Yao J, Deng M, Xie H, et al. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology. 2013;60:813–20. Gao S, Yang Z, Zheng Z, Yao J, Deng M, Xie H, et al. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology. 2013;60:813–20.
14.
Zurück zum Zitat Huang K, Zhou Q, Wang R, Cheng D, Ma Y. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:920–5. CrossRef Huang K, Zhou Q, Wang R, Cheng D, Ma Y. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:920–5. CrossRef
16.
Zurück zum Zitat Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial radioembolization with yttrium-90 for the treatment of hepatocellular carcinoma. Adv Ther. 2016;33:699–714. CrossRef Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial radioembolization with yttrium-90 for the treatment of hepatocellular carcinoma. Adv Ther. 2016;33:699–714. CrossRef
17.
Zurück zum Zitat Gaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol. 2009;16:1587–96. CrossRef Gaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol. 2009;16:1587–96. CrossRef
18.
22.
Zurück zum Zitat Song MJ. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. World J Gastroenterol. 2015;21:3843–9. CrossRef Song MJ. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. World J Gastroenterol. 2015;21:3843–9. CrossRef
23.
Zurück zum Zitat Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee DY, et al. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5‑fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer. 2007;110:129–37. CrossRef Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee DY, et al. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5‑fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer. 2007;110:129–37. CrossRef
24.
Zurück zum Zitat Lee BH, Lee DS, Cho CW, Yun SS. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A. World J Surg Oncol. 2019;17:143. CrossRef Lee BH, Lee DS, Cho CW, Yun SS. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A. World J Surg Oncol. 2019;17:143. CrossRef
25.
Zurück zum Zitat Hamaoka M, Kobayashi T, Kuroda S, Iwako H, Okimoto S, Kimura T, et al. Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: a retrospective cohort study. Int J Surg. 2017;44:223–8. CrossRef Hamaoka M, Kobayashi T, Kuroda S, Iwako H, Okimoto S, Kimura T, et al. Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: a retrospective cohort study. Int J Surg. 2017;44:223–8. CrossRef
28.
Zurück zum Zitat Lyu N, Zhao M. Hepatic arterial infusion chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase 3 trial (The FOHAIC‑1 study). J Clin Oncol. 2021;39(15_suppl):4007–4007. CrossRef Lyu N, Zhao M. Hepatic arterial infusion chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase 3 trial (The FOHAIC‑1 study). J Clin Oncol. 2021;39(15_suppl):4007–4007. CrossRef
32.
Zurück zum Zitat Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T‑Y, et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2021;39(3_suppl):267–267. CrossRef Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T‑Y, et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2021;39(3_suppl):267–267. CrossRef
33.
Zurück zum Zitat Kaseb A, Vence L, Blando J, Yadav S. Open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC. Ann Oncol. 2019;37:abstr 4098. Kaseb A, Vence L, Blando J, Yadav S. Open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC. Ann Oncol. 2019;37:abstr 4098.
34.
Zurück zum Zitat Kaseb A, Vence L, Blando J, Yadav S, Ikoma N, Pestana RC, et al. Immunologic correlates of pathologic complete response to preoperative immunotherapy in hepatocellular carcinoma. Cancer Immunol Res. 2019;7:1390–5. CrossRef Kaseb A, Vence L, Blando J, Yadav S, Ikoma N, Pestana RC, et al. Immunologic correlates of pathologic complete response to preoperative immunotherapy in hepatocellular carcinoma. Cancer Immunol Res. 2019;7:1390–5. CrossRef
35.
Zurück zum Zitat Yarchoan M, Zhu Q, Durham JN, Gross N, Charmsaz S, Leatherman JM, et al. Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2021;39(3_suppl):335–335. CrossRef Yarchoan M, Zhu Q, Durham JN, Gross N, Charmsaz S, Leatherman JM, et al. Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2021;39(3_suppl):335–335. CrossRef
Metadaten
Titel
Hepatocellular carcinoma—neoadjuvant systemic and local treatment concepts to improve resectability rates and oncological outcome
verfasst von
Iveta Urban
Florian Primavesi
Klaus Bogner
Claudia Bartsch
Marlene Trattner
Alexandra Schmid
Stefan Stättner
Publikationsdatum
03.02.2022
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00791-5